KRAS and non-small cell lung carcinoma: Similarly, mRNA vaccines, which encode the mutant KRAS protein to induce an immune response, are being investigated as monotherapy or in combination with immune checkpoint inhibitors in KRAS-mutant advanced solid tumors including NSCLC (NCT03948763, NCT05202561) [55].